Titan Pharmaceuticals Announces That Novartis Licenses Iloperidone To Vanda Pharmaceuticals Vanda to Complete Iloperidone Development SOUTH SAN FRANCISCO, Calif., June 9 /PRNewswire-FirstCall/...
Titan Initiates Phase II Clinical Studies of Pivanex(R) in Leukemia and Melanoma Patient Enrollment in Randomized Phase IIb Study in Lung Cancer Complete SOUTH SAN FRANCISCO, Calif., May 24...
Titan Announces Pivanex(R) Is Active Against Cancer-Related Genes Data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics SOUTH SAN FRANCISCO...
Titan Reports Third Quarter 2003 Results SOUTH SAN FRANCISCO, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. today reported financial results for the third quarter and...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales